DVA vs. MDLN: DaVita vs. Medline Stock Comparison

Company Profile

DaVita (DVA) and Medline (MDLN) both fall under the Health Care Equipment & Services industry group, but DVA is classified in Health Care Providers & Services while MDLN is classified in Health Care Equipment & Supplies.

DaVita (DVA) has been public since October 31, 1995, giving it decades of market history across multiple cycles, while Medline (MDLN) listed only on December 17, 2025 and lacks comparable through-cycle data.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Medline (MDLN) reports a negative beta of -0.93, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. DaVita (DVA) has a non-negative beta of 0.85.

Risk-Adjusted Performance

Risk-Return Positioning

Both DVA and MDLN need 1-year volatility and 1-year return to plot risk-return positioning.

Risk-Adjusted Metrics

Profitability

DaVita (DVA) at 96.79% clears its industry range for ROE, a sharper capital-efficiency signal than Medline (MDLN) at 4.85%, which is closer to a typical peer reading.

Both DaVita (DVA) at 6.49% and Medline (MDLN) at 1.85% keep about the typical share of revenue as profit for their industries — neither bottom line stands out from peers.

DaVita (DVA) at 15.46% operates in the top operating margin quartile, ahead of Medline (MDLN) at 5.22%, which runs around its industry’s norm.

Profitability Metrics

Growth

Only one side can be read here: DaVita (DVA) reports revenue growth of 6.46%, ranked against its industry; Medline (MDLN) has no revenue growth figure this period.

Medline (MDLN) at 117.38% clears its industry range for EPS growth, a much stronger earnings trajectory than DaVita (DVA) at -8.29%, which is closer to a typical peer reading.

Growth Metrics

Financial Strength

DaVita (DVA) at 1.41 keeps current ratio within its industry’s typical mid-range, while Medline (MDLN) at 4.04 sits above its industry’s typical mid-range — comfortable liquidity, though possibly with more idle current assets relative to peers.

Medline (MDLN) at 0.65 is near its industry mid-range for debt-to-equity ratio, while DaVita (DVA) at 11.90 sits above its benchmark range, pointing to a heavier debt load relative to equity.

Financial Strength Metrics

Dividends

Neither DaVita (DVA) nor Medline (MDLN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither DaVita (DVA) nor Medline (MDLN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

DaVita (DVA) at 14.49 sits in the cheaper P/E ratio quartile, while Medline (MDLN) at 90.09 trades above its peer range — a wide earnings-valuation gap relative to industry peers.

DaVita (DVA) at 0.85 sits in the cheaper P/S ratio quartile while Medline (MDLN) at 1.70 prices around its industry’s middle — DVA costs less per dollar of sales, though read it alongside growth and margins.

DaVita (DVA) reports a negative P/B ratio of -20.52, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Medline (MDLN) reports 2.95, ranking against industry peers normally.

Valuation Metrics